Author

Z. Rattray

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:protein structure· 2 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1

Frequent Co-Authors

G. A. Burley· 2 shared G. B. Armstrong· 2 shared V. Shah· 2 shared W. J. Lewis· 2 shared A. Lewis· 1 shared C. J. Jamieson· 1 shared C. Jamieson· 1 shared D. Berardi· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

G. A. Burley

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A first insight into the developability of an IgG3: A combined computational and experimental approach

G. B. Armstrong, A. Lewis, V. Shah, P. Taylor, C. Jamieson, G. A. Burley, W. J. Lewis, Z. Rattray

This study characterizes the developability of IgG3 mAbs using computational and experimental methods, finding poorer stability and higher viscosity compared to IgG1.

bioRxiv · Apr 29, 2024 · PreprintBioengineering

Enhancing viscosity control in antibody formulations: A framework for the biophysical screening of mutations targeting solvent-accessible hydrophobic and electrostatic patches

G. B. Armstrong, V. Shah, P. Sanches, M. Patel, R. Casey, C. J. Jamieson, G. A. Burley, W. J. Lewis, Z. Rattray

This study presents a framework for computationally screening mutations to modify antibody viscosity, showing that hydrophobic and electrostatic patches significantly affect viscosity, with positive charges causing the most increase.

bioRxiv · Mar 7, 2024 · PreprintBioengineering

The differential metabolic signature of breast cancer cellular response to olaparib treatment

D. Berardi, Y. Hunter, L. van den Driest, G. Farrell, N. J. Rattray, Z. Rattray

This study identifies cell-line and dose-dependent metabolic changes in breast cancer cells treated with olaparib, highlighting glutamine and lipid metabolism reprogramming and DNA damage foci accumulation.

bioRxiv · Jun 14, 2022Cancer Biology